PEPGEN INC. Increase Decrease In Operating Lease Liability
PEPGEN INC. (PEPG) reported Increase Decrease In Operating Lease Liability of -$1.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- PEPGEN INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$797.00K.
- PEPGEN INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$781.00K.
- PEPGEN INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$781.00K.
- PEPGEN INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$781.00K.
- PEPGEN INC. increase decrease in operating lease liability for fiscal 2025 was -$3.09M.
- PEPGEN INC. increase decrease in operating lease liability for fiscal 2024 was -$3.00M.
- PEPGEN INC. increase decrease in operating lease liability for fiscal 2023 was -$1.17M.
- PEPGEN INC. increase decrease in operating lease liability for fiscal 2022 was -$2.02M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$797.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.58M 10-Q · filed 2026-08-06 | -$2.36M derived: sum of 3 quarters · filed 2026-08-06 | -$3.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$781.00K 10-Q · filed 2026-05-12 | -$1.56M derived: sum of 2 quarters · filed 2026-05-12 | -$2.34M derived: sum of 3 quarters · filed 2026-05-12 | -$3.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$1.56M derived: sum of 2 quarters · filed 2026-03-04 | -$2.34M derived: sum of 3 quarters · filed 2026-08-06 | -$3.09M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$781.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.55M derived: sum of 2 quarters · filed 2026-08-06 | -$2.31M 10-Q · filed 2025-11-12 | -$3.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$774.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.53M 10-Q · filed 2026-08-06 | -$2.29M derived: sum of 3 quarters · filed 2026-08-06 | -$3.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$758.00K 10-Q · filed 2026-05-12 | -$1.52M derived: sum of 2 quarters · filed 2026-05-12 | -$2.27M derived: sum of 3 quarters · filed 2026-05-12 | -$4.10M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$758.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$1.52M derived: sum of 2 quarters · filed 2026-03-04 | -$3.34M derived: sum of 3 quarters · filed 2026-03-04 | -$3.00M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$758.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.58M derived: sum of 2 quarters · filed 2025-11-12 | -$2.25M 10-Q · filed 2025-11-12 | -$1.92M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.49M 10-Q · filed 2025-08-07 | -$1.17M derived: sum of 3 quarters · filed 2025-08-07 | -$1.39M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $336.00K 10-Q · filed 2025-05-08 | $659.00K derived: sum of 2 quarters · filed 2025-05-08 | $435.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.12M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $99.00K derived: sum of 2 quarters · filed 2025-02-24 | $785.00K derived: sum of 3 quarters · filed 2025-02-24 | -$1.17M 10-K · filed 2025-02-24 |
| 2023-09-30 | -$224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $462.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.49M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $686.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.26M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$1.95M 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | -$2.02M 10-K/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |